VICL

Vical CEO to Participate in Cancer Immunotherapy Panel at BIO International Convention

[at noodls] – CHICAGO, April 22, 2013 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) announced today that Vijay B. Samant, the company’s President and Chief Executive Officer, will participate in a panel discussion … moreView todays social media effects on VICLView the latest stocks trending across Twitter. Click to view dashboardSee who Vical is hiring next, click here to view […]

Vical to Present at March Investor Conferences

[at noodls] – SAN DIEGO, Feb. 27, 2013 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) today announced scheduled presentations to provide an overview of the company’s technologies, development programs, and outlook … moreView todays social media effects on VICLView the latest stocks trending across Twitter. Click to view dashboardSee who Vical is hiring next, click here to view […]

Vical Reports 2012 Financial Results and Progress in Key Development Programs

[at noodls] – SAN DIEGO, Feb. 6, 2013 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) today reported financial results for the year ended December 31, 2012. Revenues for 2012 were $17.5 million, compared with revenues … moreView todays social media effects on VICLView the latest stocks trending across Twitter. Click to view dashboardSee who Vical is hiring next, click here to […]

Vical Announces Publication of Herpes Simplex Vaccine Guinea Pig Study Data

[at noodls] – SAN DIEGO, Feb. 4, 2013 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) today announced the publication of a new article1 in the journal Vaccine detailing results from the company’s completed guinea … moreView todays social media effects on VICLView the latest stocks trending across Twitter. Click to view dashboardSee who Vical is hiring next, click here to view […]

Vical Announces News Release and Conference Call Schedule for 2012 Financial Results

[at noodls] – SAN DIEGO, Jan. 30, 2013 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months and twelve months ended December 31, 2012, … moreView todays social media effects on VICLView the latest stocks trending across Twitter. Click to view dashboardSee who Vical is hiring next, click here to […]

Vical to Present at 31st Annual J.P. Morgan Healthcare Conference

[at noodls] – SAN FRANCISCO, Jan. 3, 2013 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) today announced that the company’s President and Chief Executive Officer, Vijay B. Samant, will provide an overview of the … moreView todays social media effects on VICLView the latest stocks trending across Twitter. Click to view dashboardSee who Vical is hiring next, click here to view […]

Vical Named to NASDAQ Global Select Market

[at noodls] – SAN DIEGO, Jan. 2, 2013 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) today announced that, effective today, January 2, 2013, listing of the company’s common stock will be transferred to the NASDAQ … moreView todays social media effects on VICLView the latest stocks trending across Twitter. Click to view dashboardSee who Vical is hiring next, click here to […]

Vical Licenses Vaxfectin(R) Adjuvant to Cyvax for Use in Malaria Vaccines

[at noodls] – SAN DIEGO, Dec. 5, 2012 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) announced today a worldwide, nonexclusive license of its patented Vaxfectin® adjuvant to Cyvax, Inc., a privately held vaccine … moreView todays social media effects on VICLView the latest stocks trending across Twitter. Click to view dashboardSee who Vical is hiring next, click here to view […]

Vical to Present at Credit Suisse 2012 Healthcare Conference

[at noodls] – PHOENIX, Nov. 12, 2012 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) today announced that the company’s President and Chief Executive Officer, Vijay B. Samant, will provide an overview of the company’s … moreView todays social media effects on VICLView the latest stocks trending across Twitter. Click to view dashboard […]

Preclinical Data Support Potential Combinations for Allovectin(R) With Emerging Immunotherapies

[at noodls] – SAN DIEGO, Nov. 8, 2012 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) today announced the release of animal data at a melanoma conference documenting the benefits of combining the company’s Allovectin® … moreView todays social media effects on VICLView the latest stocks trending across Twitter. Click to view dashboard […]